Beijing Tiancheng Xinhai Pharmaceutical

Beijing Tiancheng Xinhai Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Beijing, China, dedicated to developing next-generation therapies for metabolic disorders. The company focuses on the design and optimization of multi-target peptide drugs, specifically targeting the GLP-1, GIP, and glucagon receptors. Its robust pipeline includes TCXH-101, a dual GLP-1/GIP receptor agonist in Phase 2 clinical trials for obesity and type 2 diabetes, and TCXH-201, a triple agonist aimed at treating non-alcoholic steatohepatitis (NASH). By leveraging its expertise in peptide engineering, Tiancheng Xinhai aims to provide more effective and convenient treatment options for patients worldwide. The company is supported by leading venture capital investors, including HighLight Capital and Qiming Venture Partners.